FDAAA Impact Analysis (Year 7): The Era of the “Breakthrough” REMS
This article was originally published in RPM Report
Executive Summary
FDA continues to use the formal Risk Evaluation & Mitigation Strategy authority very infrequently in the context of new drug approvals. There is one countervailing trend: the agency is imposing mandatory communication plans for some of the new oncology therapies – including two “Breakthroughs.”
You may also be interested in...
FDAAA Fading? REMS Use Continues To Decline As Drug Safety Law Matures
FDA’s use of REMS continues to fall to almost undetectable levels, with the agency using the safety tools just a handful of times in the sixth full year of the program. REMS are now very much the exception and not the rule for new products – but still a very important exception.
Carving REMS Out of Oncology? FDA, ASCO Plan Follow-Up Workshop
FDA and the oncology community will continue discussions about the role of REMS in cancer care. The agency is clearly taking pushback from providers seriously.
Rx Import Legislation: One Step Forward, Two Steps Back – And Odd Dance Partners
The strange politics of prescription drug importation legislation in the US are on display again, this time in the context of the FDA user fee reauthorization bill. Including the topic in the bill is a ‘big deal’ – but probably makes imports less likely.